

(sent by email)

14 August 2009

Dear Consultee/Commentator

## **NICE Health Technology Appraisal**

### **Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck**

As you may be aware, the Department of Health asked the Institute to conduct an appraisal of contusugene ladenovec for the treatment of unresectable recurrent and/or refractory squamous cell carcinoma of the head and neck and to provide guidance on its use to the NHS in England and Wales.

The Institute has noted that the European Medicines Agency has been formally notified by Gendux Molecular Limited of its decision to withdraw its application for a centralised marketing authorisation for this medicine. For further information please click on the following link

<http://www.emea.europa.eu/humandocs/PDFs/EPAR/contusugeneladenovecgendux/41275109en.pdf>

The Institute has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: [cathryn.hall@nice.org.uk](mailto:cathryn.hall@nice.org.uk)).

Yours sincerely

**Cathryn Hall**  
Project Manager